<section style="margin: 0px; padding: 0px; outline: 0px; max-width: 100%; color: rgba(0, 0, 0, 0.9); font-family: system-ui, -apple-system, BlinkMacSystemFont, " helvetica="" neue",="" "pingfang="" sc",="" "hiragino="" sans="" gb",="" "microsoft="" yahei="" ui",="" yahei",="" arial,="" sans-serif;="" font-size:="" 17px;="" letter-spacing:="" 0.544px;="" text-indent:="" 2em;="" line-height:="" normal;="" text-align:="" center;="" box-sizing:="" border-box="" !important;="" overflow-wrap:="" break-word="" !important;"="">½üÈÕ£¬ÍþÁ®Ï£¶ûwilliamhillҽҩЯÆìÏÂ×Ó¹«Ë¾ÃÀ¹úºº·ðÀ³¡¢²©´´Ò½Ò©ÁÁÏàÓÚÃÀ¹úSAPAÄê»á£¬ÏòÈ«ÇòÁ¢ÒìÒ©¹¤Òµ½çչʾÍþÁ®Ï£¶ûwilliamhillÍâÑóÒµÎñ£¬ÎªÍþÁ®Ï£¶ûwilliamhillÒ½Ò©ÍØÕ¹±±ÃÀ¼°¹ú¼ÊÊг¡µÓÚ¨»ù´¡¡£±¾´ÎSAPAÄê»áÒÔ“Navigating Differences to Succeed: How to Win Market in the Pharmaceutical Industry” ΪÖ÷Ì⣬º¸ÇÁËÉúÃü¿ÆÑ§Õþ²ß¹æÔò¡¢¹«¹²ÎÀÉú»Ö¸´ºÍΣ»úÔ¤·À¡¢ÉúÎïҽѧ¿ÆÑ§ÓëÁ¢Òì¡¢ÉúÎïÖÆÒ©ÉÌÎñÓëͶ×Ê¡¢Ò½Ò©ÐÐÒµÖ°ÒµÉú³¤µÈµ±ÏÂ×î»ðÈȵÄÒéÌâ¡£À´×ÔѧÊõ½ç¡¢¹¤Òµ½çºÍ¼à¹Ü»ú¹¹µÄ´ú±í£¬ÔÚµ±ÌìµÄ¼¯»áÉÏ·ÖÏíÁËѧÊõÑо¿Ç°ÑØ¡¢Ò½Ò©¼¼ÊõÈȵãÒÔ¼°¼à¹ÜÇ÷ÊÆ¡£ ÃÀÖÐÒ½Ò©¿ª·¢Ð»á£¨SAPA)ÊDZ±ÃÀ×îΪ»îÔ¾¡¢¹æÄ£×î´óµÄÒÔ»ªÈËΪÖ÷µÄÉúÎïҽҩרҵ×éÖ¯£¬¾ßÓÐ28ÄêÀúÊ·£¬Ä¿Ç°ÔÚÈ«ÇòÓÐ6000¶àÃû»áÔ±¡£×÷ΪÍþÁ®Ï£¶ûwilliamhillÒ½Ò©±±ÃÀ×Ó¹«Ë¾²©´´Ò½Ò©CEO£¬ÕÅʤ¾ü²©Ê¿ÔÚSAPAÄê»áÉÏÏò¸÷ÈË·ÖÏíÁËËûÔÚÁÙ´²Ò½Ñ§µÄ¾ÑéºÍ¶ÔÐÐÒµµÄÕ¹Íû¡£ÕÅʤ¾ü²©Ê¿ÔÚÖйúºÍÃÀ¹úÓÐÁè¼Ý30ÄêµÄÁÙ´²ºÍ»ù´¡Ñо¿¾Ñé£¬ÔøÔÚÖ£ÖÝ´óѧµÚÒ»Á¥ÊôÒ½Ôº´ÓʺôÎüҽѧÊÂÇé12Ä꣬ÔÚÄÚ¿Æ¡¢·Î²¡¡¢ÐÄÔಡѧ¡¢Ö×Áöѧ¡¢Ñ¬È¾²¡ºÍ½¡¿µÖÎÀí·½ÃæÓµÓй㷺µÄÑо¿¾Ñé¡£ÕÅʤ¾ü²©Ê¿ÓÚ1996Ä기˹̹¸£´óѧÁôѧ²¢µ£µ±ÁÙ´²Ñо¿Ô±£¬ºóÆÚÔÚÃÀ¹ú¹úÁ¢ÎÀÉúÑо¿Ôº½ÓÊܲ©Ê¿ºóÅàѵ¡£2003Ä꿪ʼÔÚÔ¼º²»ôÆÕ½ð˹Ö×Áöѧ´ÓÊÂÁÙ´²Ñо¿²¢»ñµÃÔ¼º²»ôÆÕ½ð˹´óѧ¿ÀïÉÌѧԺ½¡¿µÖÎÀí¹¤ÉÌÖÎÀí˶ʿѧλ¡£ÍþÁ®Ï£¶ûwilliamhillÒ½Ò©ÔÚ±¾´ÎSAPAÄê»áÉÏ´ó·ÅÒì²Ê£¬²»µ«Õ¹Ê¾Á˹«Ë¾µÄʵÁ¦ºÍÆ·ÅÆÐÎÏó£¬Í¬Ê±Îª½øÒ»²½¿ªÍعú¼ÊÊг¡µÓÚ¨Á˼áʵµÄ»ù´¡¡£×ó±ß-ÑîìÇ(HPC eCTDרԱÓë¹æÔòÏîÄ¿¾Àí)Öмä-ÕÅʤ¾ü½ÌÊÚ(ÍþÁ®Ï£¶ûwilliamhillÒ½Ò©±±ÃÀ×Ó¹«Ë¾²©´´Ò½Ò©CEO)ÓÒ±ß-Linda Qin(HPC BDרԱÓëÏîÄ¿¾Àí)
2023-10-26ƾ¾Ý¡¶¹ã¶«Ê¡¿ÆÑ§¼¼ÊõÌü¹ØÓÚ2023Äê¶È¹ã¶«Ê¡¿ÆÑ§¼¼Êõ½±ÌáÃûÊÂÇéµÄ֪ͨ¡·£¨ÔÁ¿Æº¯Çø×Ö¡²2023¡³1290ºÅ£©ÒªÇó£¬ÏÖ½«ÎÒµ¥Î»¼ÓÈë2023Äê¶È¹ã¶«Ê¡¿ÆÑ§¼¼Êõ½±ÌáÃûÏîÄ¿ÓйØÄÚÈݽøÐй«Ê¾£¬Ïê¼û¸½¼þ¡£ ¹«Ê¾Ê±¼ä£º2023Äê11ÔÂ3ÈÕÖÁ2023Äê11ÔÂ9ÈÕ£¬¹²7ÈÕ¡£ ¹«Ê¾ÆÚ¼ä£¬Èç¶Ô¹«Ê¾ÄÚÈÝÓÐÒìÒ飬ÇëÒÔÊéÃæÐÎʽÏòÁªÏµÈË·´Ó¦¡£ÒÔ¸öÈËÃûÒå·´Ó¦Çé¿öµÄ£¬ÇëÌá¹©ÕæÊµÐÕÃû£¨²¢Ç©Ãû£©¡¢ÁªÏµ·½·¨ºÍ·´Ó¦ÊÂÏîµÄÖ¤Ã÷ÖÊÁϵȣ»ÒÔµ¥Î»ÃûÒå·´Ó¦Çé¿öµÄ£¬ÇëÌṩµ¥Î»Ãû³Æ£¨²¢¼Ó¸Ç¹«Õ£©¡¢ÁªÏµÈË¡¢ÁªÏµ·½·¨ºÍ·´Ó¦ÊÂÏîµÄÖ¤Ã÷ÖÊÁϵȡ£·²ÄäÃûÒìÒé¡¢Áè¼ÝÆÚÏÞÒìÒéµÄ²»ÓèÊÜÀí¡£ ÁªÏµÈË£ºÁõ±ÌºÃ ÁªÏµµç»°£º15876588034 °ì¹«ËùÔÚ£º¹ãÖÝÊÐÌìºÓÇøÍò¿ÆÔÆA¶°7Â¥ ¸½¼þ£º¼ÓÈë2023Äê¶È¹ã¶«Ê¡¿ÆÑ§¼¼Êõ½±ÌáÃûÏîÄ¿ÐÅÏ¢¹«Ê¾±í ÍþÁ®Ï£¶ûwilliamhill2023Äê11ÔÂ3ÈÕ2023Äê¶È¹ã¶«Ê¡¿ÆÑ§¼¼Êõ½±¹«Ê¾±í ÏîÄ¿Ãû³ÆÖÐÒ½¾·½ÉöÔàϵͳҩÀíѧÑо¿ÌåϵµÄ¹¹½¨¼°Ó¦ÓÃÖ÷ÒªÍê³Éµ¥Î»¹ãÖÝÖÐÒ½Ò©´óѧÖ÷ÒªÍê³ÉÈË£¨Ö°³Æ¡¢Íê³Éµ¥Î»¡¢ÊÂÇ鵥룩1. ÖܾÁÑþ£¨½ÌÊÚ£¬Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ£¬ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧ£©£¨Ö÷ҪТ¾´£ºÏîÄ¿×ÜÂôÁ¦ÈË£¬Öƶ¨×ÜÌåÑо¿Ë¼Â·ºÍ¼Æ»®£¬Í³³ï¿ÎÌâÉè¼ÆÓëʵʩ£©2. Áº´ºÁᣨ¸±Ñо¿Ô±£¬Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ£¬ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧ£©£¨Ö÷ҪТ¾´£ºÂôÁ¦¿ÎÌâÉè¼ÆÓëʵʩ¼°ÂÛÎÄÐû²¼£©3. Îâ¿¡±ê£¨¸±Ö÷ÈÎҩʦ£¬Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ£¬ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧ£©£¨Ö÷ҪТ¾´£ºÂôÁ¦¿ÎÌâÉè¼ÆÓëʵʩ£¬ÂÛÎÄÐû²¼¼°½á¹ûÁÙ´²Ó¦ÓÃÍÆ¹ã£©4. ÖÜÔ°£¨½ÌÊÚ£¬Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ£¬ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧ£©£¨Ö÷ҪТ¾´£ºÂôÁ¦×éÖ¯ÏîĿʵʩºÍ¿ÎÌâÉè¼ÆÓÅ»¯£¬ÂÛÎÄÐû²¼£©5. ÁÖ»Ô£¨Ñо¿Ô±£¬Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ£¬ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧ£©£¨Ö÷ҪТ¾´£ºÐÖú¿ÎÌâÉè¼ÆÓëʵʩ¼°½á¹ûÍÆ¹ã£©6. Áõ±ÌºÃ£¨ÖúÀíÑо¿Ô±£¬Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ£¬ÊÂÇ鵥λ£ºÍþÁ®Ï£¶ûwilliamhill£©£¨Ö÷ҪТ¾´£º¼ÓÈë¿ÎÌâʵʩÓëÂÛÎÄÐû²¼¼°½á¹ûÐÂÒ©Ñз¢£©7. ¹ÅÔÂ褣¨¸±Ñо¿Ô±£¬Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ£¬ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧ(Ö÷ҪТ¾´£ºÐÖú¿ÎÌâÉè¼ÆÓëʵʩ¼°½á¹ûÍÆ¹ã£©8. ³Â¿¡÷裨ÎÞ£¬Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ£¬ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧ£©£¨Ö÷ҪТ¾´£º¼ÓÈë¿ÎÌâʵʩÓëÂÛÎÄÐû²¼¼°½á¹ûת»¯Íƹ㣩´ú±íÐÔÂÛÎÄ×¨ÖøÄ¿Â¼ÂÛÎÄ1£º Integrated Fecal Microbiome and Serum Metabolomics Analysis Reveals Abnormal Changes in Rats with Immunoglobulin A Nephropathy and the Intervention Effect of Zhen Wu Tang£¨ÆÚ¿¯£ºFrontiers in Pharmacology£¬Äê¾í£º2021Äê12¾í£¬µÚÒ»×÷ÕߣºÀî¼Ì³Ç£¬Í¨Ñ¶×÷ÕߣºÖܾÁÑþ£©ÂÛÎÄ2£º Zhen-wu-tang attenuates Adriamycin-induced nephropathy via regulating AQP2 and miR-92b£¨ÆÚ¿¯£ºBiomedicine & Pharmacotherapy£¬Äê¾í£º2019Äê109¾í£¬µÚÒ»×÷ÕߣºÁº´ºÁá¡¢ÕÅÅà´¿£¬Í¨Ñ¶×÷ÕߣºÖܾÁÑþ£©ÂÛÎÄ3£º Zhen-wu-tang ameliorates membranous nephropathy rats through inhibiting NF-κB pathway and NLRP3 inflammasome£¨ÆÚ¿¯£ºPhytomedicine£¬Äê¾í£º2019Äê59¾í£¬µÚÒ»×÷ÕߣºÁõ±ÌºÃ£¬Í¨Ñ¶×÷ÕߣºÖܾÁÑþ£©ÂÛÎÄ4£º Zhen-wu-tang protects against podocyte injury in rats with IgA nephropathy via PPARγ/NF-κB pathway£¨ÆÚ¿¯£ºBiomedicine & Pharmacotherapy£¬Äê¾í£º2018Äê101¾í£¬µÚÒ»×÷ÕߣºÁõ±ÌºÃ£¬Í¨Ñ¶×÷ÕߣºÖܾÁÑþ£¬ÖÜÔ°£©ÂÛÎÄ5£ºÕæÎäÌÀË®ÌáÒºHPLCÌØÕ÷ͼÆ×Ñо¿¼°Ö¸±êÉí·ÖµÄ²â¶¨£¨ÆÚ¿¯£ºÖйúʵÑé·½¼ÁѧÔÓÖ¾£¬Äê¾í£º2018Äê20¾í£¬µÚÒ»×÷ÕߣºÎâ¿¡±ê£¬Í¨Ñ¶×÷ÕߣºÖܾÁÑþ£©ÖªÊ¶²úȨÃû³Æ×¨Àû1£ºÇʰ±´¼-1-Á×Ëá4ÊÜÌ弤¶¯¼Á¼°ÆäÓëÕæÎäÌÀÁªºÏÔÚÖÆ±¸ÖÎÁÆÂýÐÔÉöСÇòÉöÑ×Ò©ÎïÖеÄÓ¦Óã¨×¨ÀûÊÚȨºÅ£ºCN 113332435 B£¬·¢Ã÷ÈË£ºÖܾÁÑþ¡¢³Â¿¡÷è¡¢ÖÜÔ°¡¢Ëï½ðÅô¡¢Â¬ÈðÈð¡¢Îâãëç죬ȨÀûÈË£º¹ãÖÝÖÐÒ½Ò©´óѧ£©
2023-11-03ƾ¾Ý¡¶¹ã¶«Ê¡¿ÆÑ§¼¼ÊõÌü¹ØÓÚ2023Äê¶È¹ã¶«Ê¡¿ÆÑ§¼¼Êõ½±ÌáÃûÊÂÇéµÄ֪ͨ¡·ÔÁ¿Æº¯Çø×Ö¡²2023¡³1290ºÅÒªÇó£¬ÏÖ½«ÎÒµ¥Î»¼ÓÈë2023Äê¶È¹ã¶«Ê¡¿ÆÑ§¼¼Êõ½±ÌáÃûÏîÄ¿ÓйØÄÚÈݽøÐй«Ê¾£¬Ïê¼û¸½¼þ¡£ ¹«Ê¾Ê±¼ä£º2023Äê10ÔÂ31ÈÕÖÁ2023Äê11ÔÂ6ÈÕ£¬¹²7ÈÕ¡£ ¹«Ê¾ÆÚ¼ä£¬Èç¶Ô¹«Ê¾ÄÚÈÝÓÐÒìÒ飬ÇëÒÔÊéÃæÐÎʽÏòÁªÏµÈË·´Ó¦¡£ÒÔ¸öÈËÃûÒå·´Ó¦Çé¿öµÄ£¬ÇëÌá¹©ÕæÊµÐÕÃû£¨²¢Ç©Ãû£©¡¢ÁªÏµ·½·¨ºÍ·´Ó¦ÊÂÏîµÄÖ¤Ã÷ÖÊÁϵȣ»ÒÔµ¥Î»ÃûÒå·´Ó¦Çé¿öµÄ£¬ÇëÌṩµ¥Î»Ãû³Æ£¨²¢¼Ó¸Ç¹«Õ£©¡¢ÁªÏµÈË¡¢ÁªÏµ·½·¨ºÍ·´Ó¦ÊÂÏîµÄÖ¤Ã÷ÖÊÁϵȡ£·²ÄäÃûÒìÒé¡¢Áè¼ÝÆÚÏÞÒìÒéµÄ²»ÓèÊÜÀí¡£ ÁªÏµÈË£º»ÆÀöÑÅ ÁªÏµµç»°£º22201200 °ì¹«ËùÔÚ£º¹ãÖÝÊÐ»ÆÆÒÇø¿ÆÑ§³ÇÄÏÏèһ·62ºÅ ¸½¼þ£º¼ÓÈë2023Äê¶È¹ã¶«Ê¡¿ÆÑ§¼¼Êõ½±ÌáÃûÏîÄ¿ÐÅÏ¢¹«Ê¾±íÍþÁ®Ï£¶ûwilliamhill2023Äê10ÔÂ31ÈÕ ¸½¼þ£º ¼ÓÈë2023Äê¶È¹ã¶«Ê¡¿ÆÑ§¼¼Êõ½±ÌáÃûÏîÄ¿ÐÅÏ¢¹«Ê¾±í ÏîÄ¿Ãû³ÆÖÐÒ©“ÈËÓþÑ锼¼ÊõÌåϵ¹¹½¨ÓëÍÆ¹ãÓ¦ÓÃÖ÷ÒªÍê³Éµ¥Î»¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº³É¶¼ÖÐÒ½Ò©´óѧÁ¥ÊôÒ½ÔºÉϺ£ÖÐÒ½Ò©´óѧÁ¥ÊôÊï¹âÒ½ÔºÍþÁ®Ï£¶ûwilliamhill»ªÈóÈý¾ÅÒ½Ò©¹É·ÝÓÐÏÞ¹«Ë¾Ö÷ÒªÍê³ÉÈË£¨Ö°³Æ¡¢Íê³Éµ¥Î»¡¢ÊÂÇ鵥룩1.ÑîÖÒÆæ£¨Ö°³Æ£ºÖ÷ÈÎÖÐҽʦ¡¢ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Ö÷ҪТ¾´£ºÇ£Í·Ìá³öÖÐÒ©“ÈËÓþÑé”ÀíÂÛ£¬Æð²ÝÏà¹Ø¼¼ÊõÎļþ¡¢×¨¼Ò¹²Ê¶ºÍѧÊõÂÛÎÄ£¬ ¹¹½¨ÖÐÒ©ÈËÓþÑé¼¼ÊõÌåϵ£»¹ð֦ͨÂçÆ¬¡¢Çå»¯Ñø·Î¿ÅÁ£µÄ´¦·½·¢Ã÷ÈË£»Ö÷³ÖÒ½ÔºÖÆ¼Áε¨Æ¬¡¢ÐÄÑôƬµÈµÄÑо¿ºÍ¿ª·¢¡££©2.ÌÆ½¡Ôª£¨Ö°³Æ£ºÑо¿Ô±¡¢ÊÂÇ鵥λ£º³É¶¼ÖÐÒ½Ò©´óѧÁ¥ÊôÒ½Ôº¡¢Íê³Éµ¥Î»£º³É¶¼ÖÐÒ½Ò©´óѧÁ¥ÊôÒ½Ôº¡¢Ö÷ҪТ¾´£ºÅäºÏ×éÖ¯Öйúҩѧ»áÖÐÒ©ÁÙ´²ÆÀ¼Ûרί»áÌÖÂÛÖÐÒ©ÁÙ´²ÆÀ¼ÛÖб£´æµÄÎÊÌ⣬ »ý¼«¹¹½¨ÖÐÒ©“ÈËÓþÑé”ÀíÂÛÌåϵ¡£ µ£µ±¹ú¼ÒÒ©¼à¾ÖÒ©ÉóÖÐÐÄÖÐÒ©Ãñ×åÒ©ÁÙ´²²¿²¿ºã¾Ã¼ä£¬Ìá³ö²¢×é֯ר¼ÒÌÖÂÛ¹¹½¨»ùÓÚÈËÓþÑéµÄÖÐÒ©ÁÙ´²ÆÀ¼Û¼¼ÊõÌåϵ¡££©3.ԪΨ°²£¨Ö°³Æ£ºÖ÷ÈÎҽʦ¡¢ÊÂÇ鵥λ£ºÉϺ£ÖÐÒ½Ò©´óѧÁ¥ÊôÊï¹âÒ½Ôº¡¢Íê³Éµ¥Î»£ºÉϺ£ÖÐÒ½Ò©´óѧÁ¥ÊôÊï¹âÒ½Ôº¡¢Ö÷ҪТ¾´£ºÅäºÏ×éÖ¯Öйúҩѧ»áÖÐÒ©ÁÙ´²ÆÀ¼Ûרί»áÌÖÂÛÖÐÒ©ÁÙ´²ÆÀ¼ÛÖб£´æµÄÎÊÌ⣬»ý¼«¹¹½¨ÖÐÒ©“ÈËÓþÑé”ÀíÂÛ¡£ºã¾Ã´ÓÊÂÖÐÒ©ÐÂÒ©ÁÙ´²ÊÔÑéÊÂÇ飬֨ÊÓÖÐÒ©ÈËÓþÑé×ÊÁÏÖÊÁ¿£¬Îª¹¹½¨»ùÓÚÈËÓþÑéµÄÖÐÒ©ÁÙ´²ÆÀ¼Û¼¼ÊõÌåϵ×ö³öÖØÒªÐ¢¾´¡££©4.ÙþÉÜÏ飨ְ³Æ£ºÖ÷ÈÎÖÐҽʦ¡¢ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Ö÷ҪТ¾´£ºÒ½ÔºÖƼÁε¨Æ¬¡¢ÐÄÑôƬµÄ´¦·½·¢Ã÷ÈË¡£¿ªÕ¹Ò½ÔºÖƼÁε¨Æ¬¡¢ÐÄÑôƬµÄÈËÓþÑéÑо¿¡£·¢Ã÷רÀû“Ò»ÖÖ¼ì²âε¨Æ¬¹¤ÒÕÎȶ¨ÐÔµÄÒªÁ씵ĵÚÒ»·¢Ã÷ÈË¡££©5.ÍõÁÁ£¨Ö°³Æ£ºÖ÷¹Üҩʦ¡¢ÊÂÇ鵥λ£º»ªÈóÈý¾ÅÒ½Ò©¹É·ÝÓÐÏÞ¹«Ë¾¡¢Íê³Éµ¥Î»£º»ªÈóÈý¾ÅÒ½Ò©¹É·ÝÓÐÏÞ¹«Ë¾¡¢Ö÷ҪТ¾´£º»ùÓÚÖÐÒ©“ÈËÓþÑé” ¼¼ÊõÌåϵ½øÐÐÒ©ÎïÉÏÊкóÁÙ´²¼ÛÖµÔÙÆÀ¼ÛºÍÄþ¾²ÐÔÆÀ¼Û¡££©6.Ì·²¨£¨Ö°³Æ£ºÎÞ¡¢ÊÂÇ鵥λ£ºÍþÁ®Ï£¶ûwilliamhill¡¢Íê³Éµ¥Î»£ºÍþÁ®Ï£¶ûwilliamhill¡¢Ö÷ҪТ¾´£º»ùÓÚÖÐÒ©“ÈËÓþÑé” ¼¼ÊõÌåϵΪȫ¹ú¸÷µØÆóҵЧÀÍ£¬ÐÖúÆóÒµ»ñµÃ¹ú¼ÒÒ©¼à¾ÖÖÐÒ©ÐÂÒ©ÁÙ´²ÊÔÑéÐí¿É£¬¿ªÕ¹ÖÐÒ©ÐÂÒ©ÁÙ´²ÊÔÑéÏîÄ¿¡££©7.³·£¨Ö°³Æ£ºÎÞ¡¢ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Ö÷ҪТ¾´£ºÐÖú¹¹½¨ÖÐÒ©“ÈËÓþÑ锼¼ÊõÌåϵ£¬¼ÓÈë׫дÖÐÒ©“ÈËÓþÑé”Ïà¹Ø×¨¼Ò¹²Ê¶ºÍѧÊõÂÛÎÄ¡£ÔÚÈ«¹úÍÆ¹ãÖÐÒ©“ÈËÓþÑ锼¼ÊõÌåϵ¡£·¢Ã÷רÀû“Ò»ÖÖÔ¤²âÖÐÒ©¸´·½Ö±½Ó°ÐµãºÍ×÷ÓÃÉí·ÖµÄÒªÁ씵ĵÚÒ»·¢Ã÷ÈË¡££©8.ÌÆÑÅÇÙ£¨Ö°³Æ£ºÖ÷ÖÎҽʦ¡¢ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Ö÷ҪТ¾´£ºÐÖú¹¹½¨ÖÐÒ©“ÈËÓþÑ锼¼ÊõÌåϵ£¬¼ÓÈë׫дÖÐÒ©“ÈËÓþÑé”Ïà¹Ø×¨¼Ò¹²Ê¶ºÍѧÊõÂÛÎÄ¡£ÔÚÈ«¹úÍÆ¹ãÖÐÒ©“ÈËÓþÑ锼¼ÊõÌåϵ¡££©9.ÄßÊÀºÀ£¨Ö°³Æ£ºÒ½Ê¦¡¢ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Ö÷ҪТ¾´£ºÐÖú¹¹½¨ÖÐÒ©“ÈËÓþÑ锼¼ÊõÌåϵ£¬¼ÓÈë׫дÖÐÒ©“ÈËÓþÑé”Ïà¹Ø×¨¼Ò¹²Ê¶ºÍѧÊõÂÛÎÄ¡£ÔÚÈ«¹úÍÆ¹ãÖÐÒ©“ÈËÓþÑ锼¼ÊõÌåϵ¡££©10.ÌÀ»ÛÃô£¨Ö°³Æ£ºÒ½Ê¦¡¢ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Ö÷ҪТ¾´£ºÐÖú¹¹½¨ÖÐÒ©“ÈËÓþÑ锼¼ÊõÌåϵ£¬¼ÓÈë׫дÖÐÒ©“ÈËÓþÑé”Ïà¹Ø×¨¼Ò¹²Ê¶ºÍѧÊõÂÛÎÄ¡£ÔÚÈ«¹úÍÆ¹ãÖÐÒ©“ÈËÓþÑ锼¼ÊõÌåϵ¡££©11.ÁèÑְࣨ³Æ£º¸±Ö÷ÈÎҽʦ¡¢ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢Ö÷ҪТ¾´£ºÐÖú¹¹½¨ÖÐÒ©“ÈËÓþÑ锼¼ÊõÌåϵ£¬¼ÓÈë׫дÖÐÒ©“ÈËÓþÑé”Ïà¹Ø×¨¼Ò¹²Ê¶ºÍѧÊõÂÛÎÄ¡£ÔÚÈ«¹úÍÆ¹ãÖÐÒ©“ÈËÓþÑ锼¼ÊõÌåϵ¡££©´ú±íÐÔÂÛÎÄ×¨ÖøÄ¿Â¼ÂÛÎÄ1£º<Ãû³Æ£º¡¶ÖÐÒ©ÈËÓþÑéÑо¿×¨¼Ò¹²Ê¶¡·¡¢ÆÚ¿¯£ºÖйúÖÐÒ©ÔÓÖ¾¡¢Äê¾í£º2022,47(18)¡¢µÚÒ»×÷ÕߣºÑîÖÒÆæ¡¢Í¨Ñ¶×÷ÕߣºÑîÖÒÆæ>ÂÛÎÄ2£º<Ãû³Æ£º¡¶ÊÔÂÛÖÐÒ©ÈËÓþÑé×ÊÁÏÊÕ¼¯¡¢Êý¾ÝÖÊÁ¿ÓëÖ¤¾ÝÐγɡ·¡¢ÆÚ¿¯£ºÖйúÖÐÒ©ÔÓÖ¾¡¢Äê¾í£º2021,46(07)¡¢µÚÒ»×÷ÕߣºÑîÖÒÆæ¡¢Í¨Ñ¶×÷ÕߣºÑîÖÒÆæ>ÂÛÎÄ3£º<Ãû³Æ£º¡¶ÊÔÂÛÕæÊµÊÀ½çÑо¿ÓëÈËÓþÑéÔÚÖÐÒ©ÐÂÒ©Ñз¢ÖеÄÓ¦Óá·¡¢ÆÚ¿¯£ºÖйúÖÐÒ©ÔÓÖ¾¡¢Äê¾í£º2021,46(22)¡¢µÚÒ»×÷ÕߣºÑîÖÒÆæ¡¢Í¨Ñ¶×÷ÕߣºÑîÖÒÆæ>ÂÛÎÄ4£º<Ãû³Æ£º¡¶ÖÐÒ©ÈËÓþÑéÑо¿µÄÖÊÁ¿ÒªÇó¡·¡¢ÆÚ¿¯£ºÖйúÖÐÒ©ÔÓÖ¾¡¢Äê¾í£º2023,48(17)¡¢µÚÒ»×÷ÕߣºÌÆÑÅÇÙ¡¢Í¨Ñ¶×÷ÕߣºÑîÖÒÆæ>ÂÛÎÄ5£º<Ãû³Æ£º¡¶´«³ÐÁ¢Òì——ÖÐÒ©×¢²á¼à¹ÜÕ½ÂÔÛ»Òé¡·¡¢ÆÚ¿¯£º¿ÆÑ§Í¨±¨¡¢Äê¾í£º2023,68(05)¡¢µÚÒ»×÷ÕߣºÌƽ¡Ôª¡¢Í¨Ñ¶×÷ÕߣºÌƽ¡Ôª>֪ʶ²úȨÃû³Æ×¨Àû1£º<Ò»ÖÖйڷÎÑ׿µ¸´ÖÎÁÆÖÐÒ©×éºÏÎï¼°ÆäÓ¦ÓÃ>£¨×¨ÀûÊÚȨºÅ£ºCN 114984166 B¡¢·¢Ã÷ÈË£ºÑîÖÒÆæ¡¢È¨ÀûÈË£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº£©×¨Àû2£º<Ò»ÖÖÔ¤²âÖÐÒ©¸´·½Ö±½Ó°ÐµãºÍ×÷ÓÃÉí·ÖµÄÒªÁì>£¨×¨ÀûÊÚȨºÅ£ºCN 110322929 B¡¢·¢Ã÷ÈË£ºÂ³Â·£¬ÄßÊÀºÀ£¬ËïÊõÄþ¡¢È¨ÀûÈË£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº£©×¨Àû3£º<Ò»ÖÖ¼ì²âε¨Æ¬¹¤ÒÕÎȶ¨ÐÔµÄÒªÁì>£¨×¨ÀûÊÚȨºÅ£ºCN 106323794 B¡¢·¢Ã÷ÈË£ºÙþÉÜÏ顢ȨÀûÈË£º¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»Á¥ÊôÒ½Ôº£©ÐÂÒ©¿ª·¢1£º<ε¨Æ¬>£¨Åú¼þºÅ£º2016L05845£©ÐÂÒ©¿ª·¢2£º<ÐÄÑôƬ>£¨Åú¼þºÅ£º2022LP01399£©ÔºÄÚÖÆ¼Á1£º<¹ð֦ͨÂçÆ¬>£¨Åú¼þºÅ£ºZ20220002£©ÔºÄÚÖÆ¼Á2£º<Çå»¯Ñø·Î¿ÅÁ£>£¨Åú¼þºÅ£ºZ2023000500£©
2023-10-311111MicrosoftInternetExplorer402DocumentNotSpecified7.8 °õNormal0Ö×ÁöÄ£ÐÍÁܰÍÁö»îÌå³ÉÏñ1111MicrosoftInternetExplorer402DocumentNotSpecified7.8 °õNormal01111MicrosoftInternetExplorer402DocumentNotSpecified7.8 °õNormal0¶¯ÎïÄ£ÐÍ´óÊóÂýÐÔÐÄ˥ģÐÍ1111MicrosoftInternetExplorer402DocumentNotSpecified7.8 °õNormal0ÌÇÄò²¡¼°DKD¶¯ÎïÄ£ÐÍ 1111MicrosoftInternetExplorer402DocumentNotSpecified7.8 °õNormal0¹ÇÊàŦÑ×Ä£ÐÍ1111MicrosoftInternetExplorer402DocumentNotSpecified7.8 °õNormal0·ÎÏËά»¯1111MicrosoftInternetExplorer402DocumentNotSpecified7.8 °õNormal0¸ÉÑÛÖ¢
2023-10-10ÔÁ¹«Íø°²±¸ 44011202001884ºÅ
ÔÁ¹«Íø°²±¸ 44011202001884ºÅ